-

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:

  • Canaccord Genuity's 45th Annual Growth Conference
    Boston, Massachusetts
    Fireside chat: Tuesday, August 12 at 8:00 a.m. ET
  • 2025 Wells Fargo Healthcare Conference
    Boston, Massachusetts
    Fireside chat: Thursday, September 4 at 2:15 p.m. ET
  • Morgan Stanley 23rd Annual Global Healthcare Conference
    New York, New York
    Fireside chat: Monday, September 8 at 8:30 a.m. ET

Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Contacts

Investor Relations:
Investors@GeneDx.com

Media:
Press@GeneDx.com

Industry:

GeneDx

NASDAQ:WGS
Release Summary
GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.
Release Versions
English

Contacts

Investor Relations:
Investors@GeneDx.com

Media:
Press@GeneDx.com

More News From GeneDx

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing...

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GAITHERSBURG, Md.--(BUSINESS WIRE)--Announcing GeneDx's new genetic testing program with Zevra Therapeutics to support patients with suspected Niemann–Pick disease type C (NPC)....

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation...
Back to Newsroom